NCT05575323

Brief Summary

The BLEND RCT aims to evaluate the (cost-)effectiveness of same-day SBRT and surgical stabilization with or without decompression for the treatment of symptomatic, unstable spinal metastases on physical functioning four weeks after the start of treatment, compared with the standard of care (surgery followed by radiotherapy as soon as the wound healed sufficiently).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
14mo left

Started Oct 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress76%
Oct 2022Jun 2027

First Submitted

Initial submission to the registry

September 29, 2022

Completed
13 days until next milestone

First Posted

Study publicly available on registry

October 12, 2022

Completed
3 days until next milestone

Study Start

First participant enrolled

October 15, 2022

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2027

Last Updated

April 3, 2025

Status Verified

March 1, 2025

Enrollment Period

3.7 years

First QC Date

September 29, 2022

Last Update Submit

March 31, 2025

Conditions

Keywords

Spinal metastasesSBRTSurgerySame-day treatmentRCT

Outcome Measures

Primary Outcomes (1)

  • Physical functioning

    Physical functioning is a functional scale from the EORTC QLQ-C15-PAL questionnaire. Patients rate each item on a 4-point Likert scale ranging from 1 (not at all) to 4 (very much), and scale scores were linearly transformed to a 0-100 scale. A higher score on the functional scale indicates better functioning.

    at 4 weeks after the start of treatment

Secondary Outcomes (11)

  • Pain response

    at 2, 4, 6 and 8 weeks, and 3 months after the start of treatment

  • Duration of pain relief

    up to 3 months

  • Duration of hospital stay

    up to 3 months

  • Days until return to systemic treatment

    up to 12 months

  • Neurological deterioration

    up to 12 months

  • +6 more secondary outcomes

Other Outcomes (1)

  • Cost-effectiveness

    up to 12 months

Study Arms (2)

Intervention

EXPERIMENTAL

Patients will receive high dose, single fraction stereotactic body radiotherapy (SBRT) using differential dosing: 18 or 21 Gy on the metastasis. Within 24 hours after SBRT, patients will have surgical stabilization with or without decompression.

Other: Same-day SBRT and spinal surgery

Control

ACTIVE COMPARATOR

Patients will undergo the standard of care, which is surgical stabilization with or without decompression, followed by conventional radiotherapy (cRT) or SBRT as soon as the wound is healed sufficiently.

Other: Standard of care

Interventions

SBRT and surgical stabilization with or without decompression within 24 hours

Intervention

Surgical stabilization with or without decompression followed by cRT or SBRT as soon as the wound is healed sufficiently

Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Symptomatic (cervical, thoracic and/or lumbar) spinal metastases from solid tumors and (impending) spinal instability requiring radiotherapy and surgical decompression and/or stabilization
  • Histologic proof of malignancy or radiographic/clinical characteristics indicating malignancy beyond reasonable doubt
  • Radiographic evidence of spinal metastases
  • Participation in PRESENT cohort, including consent for randomization into future trials
  • Fit for (radio)surgery
  • Age \>18 years
  • Written informed consent

You may not qualify if:

  • SBRT cannot be delivered, e.g. in patients who cannot lie on the treatment table because of pain
  • Routine surgical decompression and/or stabilization and radiotherapy cannot be performed, e.g., multiple spinal metastases requiring surgical bridging of more than five vertebral levels and/or requiring radiotherapy on more than one location
  • Prior surgery or radiotherapy to the index level(s)
  • Multiple myeloma
  • Neurological deficits (ASIA C, B or A), or partial neurological deficits (ASIA D) with rapid progression (hours to days)
  • Treated with Bevacizumab and other medication with long half-life that interferes with radiotherapy
  • Life expectancy of less than 3 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Medical Center Utrecht

Utrecht, Netherlands

RECRUITING

Related Publications (1)

  • Huele EH, van der Velden JM, Kasperts N, Eppinga WSC, Grutters JPC, Suelmann BBM, Weening AA, Delawi D, Teunissen SCCM, Verkooijen HM, Verlaan JJ, Gal R. Stereotactic Body radiotherapy and pedicLE screw fixatioN During one hospital visit for patients with symptomatic unstable spinal metastases: a randomized trial (BLEND RCT) using the Trials within Cohorts (TwiCs) design. Trials. 2023 May 4;24(1):307. doi: 10.1186/s13063-023-07315-y.

MeSH Terms

Interventions

Standard of Care

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Officials

  • Helena M. Verkooijen, Prof

    UMC Utrecht

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Roxanne Gal, PhD

CONTACT

Eline Huele, MSc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
According to the TwiCs design, patients allocated to the control group are not informed about their role as a control in the trial.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. H.M. Verkooijen

Study Record Dates

First Submitted

September 29, 2022

First Posted

October 12, 2022

Study Start

October 15, 2022

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

June 30, 2027

Last Updated

April 3, 2025

Record last verified: 2025-03

Locations